Search
MOD-5014
go.drugbank.com/drugs/DB17715InvestigationalMOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa.[A259088] It is being investigated for the treatment of hemophilia.[L46173]
mRNA-3351
go.drugbank.com/drugs/DB17718ExperimentalmRNA-3351 is a modified mRNA encoding the UGT1A1 gene. Developed by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome
NM3086
go.drugbank.com/drugs/DB17719ExperimentalNM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.[L46193]
OMS906
go.drugbank.com/drugs/DB17722InvestigationalOMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.
Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigationalRusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera. … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
CSL-689
go.drugbank.com/drugs/DB17726InvestigationalCSL689 is a recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
MBP-091
go.drugbank.com/drugs/DB17741ExperimentalMBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]
Respiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigationalArexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals. It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusi...
Synonyms: RSVPreF3 OA, RSVPreF3 OA vaccineAVP-21D9
go.drugbank.com/drugs/DB17798InvestigationalAVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.[A259522]
Perfluorohexyloctane
go.drugbank.com/drugs/DB17823ApprovedInvestigational[A259746, A259751] Perfluorohexyloctane has been used in the field of ophthalmology as a vitreous substitute. … [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.